Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Dig Dis ; 21(1): 38-45, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31714673

RESUMO

OBJECTIVES: The activation of the adenosine A3 receptor (A3AR) can regulate inflammation, but the way that this regulates colonic mucosal inflammation in ulcerative colitis (UC) remains unclear. This study aimed at examining A3AR expression and investigating the effect of A3AR activation on ex vivo cytokine expression and nuclear factor-kappa B (NF-κB) signaling in colonic mucosa. METHODS: Colonic mucosal biopsied tissue from 18 patients with UC and 11 healthy controls was tested for A3AR expression by immunofluorescence, quantitative real-time polymerase chain reaction and Western blot. Following treatment for 24 hours with or without 2-Cl-IB-MECA, an A3AR agonist, TNF-α and IL-1ß secreted by the cultured colonic mucosal tissue were quantified by ELISA. The colonic mucosal epithelia were dissected and treated with, or without 2-Cl-IB-MECA for 24 hours. The NF-κB p65 protein and its distribution in the cultured colonic epithelia were examined by immunofluorescence and Western blot. RESULTS: Compared with the controls, down-regulated A3AR expression and up-regulated TNF-α and IL-1ß production and NF-κB p65 protein were observed in the UC colonic mucosa. The activation of A3AR by 2-Cl-IB-MECA significantly decreased TNF-α and IL-1ß production and attenuated the NF-κB p65 activation in colonic tissues from patients with UC. CONCLUSIONS: A3AR activation inhibited inflammation by mitigating pro-inflammatory cytokine production and the NF-κB signal activation in colonic mucosa of patients with UC. A3AR activation may play a role in the pathogenesis of UC.


Assuntos
Adenosina/análogos & derivados , Colite Ulcerativa/imunologia , Colo/imunologia , NF-kappa B/metabolismo , Agonistas do Receptor Purinérgico P1/farmacologia , Receptor A3 de Adenosina/imunologia , Adenosina/farmacologia , Adenosina/uso terapêutico , Colite Ulcerativa/tratamento farmacológico , Colo/efeitos dos fármacos , Citocinas/antagonistas & inibidores , Citocinas/biossíntese , Citocinas/imunologia , Regulação para Baixo , Humanos , Inflamação/tratamento farmacológico , Inflamação/imunologia , Interleucina-1beta/biossíntese , Interleucina-1beta/imunologia , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/imunologia , NF-kappa B/biossíntese , Fragmentos de Peptídeos/biossíntese , Fragmentos de Peptídeos/imunologia , Agonistas do Receptor Purinérgico P1/uso terapêutico , Receptor A3 de Adenosina/biossíntese , Transdução de Sinais , Fator de Necrose Tumoral alfa/biossíntese , Fator de Necrose Tumoral alfa/imunologia , Regulação para Cima
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA